Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis
- PMID: 28656804
- DOI: 10.1080/14656566.2017.1346085
Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis
Abstract
Olopatadine hydrochloride is an antihistamine and mast cell stabilizer available as oral, intranasal and ocular preparations. Most of the practical applications of olopatadine therapy focus on the treatment of allergic rhinoconjunctivitis via intranasal and ocular routes. Areas covered: This article was created from a comprehensive literature search with information taken from meta-analyses, systematic reviews, and clinical trials of children and adults. The articles that have been selected, evaluate the use of intranasal and ocular antihistamines and their role in allergic rhinoconjunctivitis. Expert opinion: Olopatadine is significantly more effective than placebos in relieving the symptoms of allergic rhinoconjunctivitis. It can function both as a viable alternative or addition to first line therapies such as intranasal steroids and oral antihistamines.
Keywords: Allergic conjunctivitis; allergic rhinitis; antihistamine; mast cell stabilizer; olopatadine; rhinoconjunctivitis; treatment.
Similar articles
-
Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis.Expert Opin Drug Metab Toxicol. 2011 Dec;7(12):1593-9. doi: 10.1517/17425255.2011.630389. Epub 2011 Oct 28. Expert Opin Drug Metab Toxicol. 2011. PMID: 22032416 Review.
-
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.Clin Ther. 2002 Jul;24(7):1161-74. doi: 10.1016/s0149-2918(02)80027-3. Clin Ther. 2002. PMID: 12182260 Clinical Trial.
-
Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis.Ocul Immunol Inflamm. 2017 Oct;25(5):663-677. doi: 10.3109/09273948.2016.1158282. Epub 2016 May 18. Ocul Immunol Inflamm. 2017. PMID: 27192186
-
Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):453-61. doi: 10.1517/17425255.4.4.453. Expert Opin Drug Metab Toxicol. 2008. PMID: 18433347 Review.
-
Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.Am J Ophthalmol. 1998 Jun;125(6):797-804. doi: 10.1016/s0002-9394(98)00044-0. Am J Ophthalmol. 1998. PMID: 9645717 Clinical Trial.
Cited by
-
Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.Ocul Surf. 2021 Jul;21:66-77. doi: 10.1016/j.jtos.2021.05.004. Epub 2021 May 15. Ocul Surf. 2021. PMID: 34000363 Free PMC article. Review.
-
Development of a Temperature and pH Dual-Sensitive In-Situ Gel for Treating Allergic Conjunctivitis.AAPS PharmSciTech. 2024 Sep 25;25(7):223. doi: 10.1208/s12249-024-02931-6. AAPS PharmSciTech. 2024. PMID: 39322789
-
Relevance of IgE, allergy and eye rubbing in the pathogenesis and management of Keratoconus.Indian J Ophthalmol. 2020 Oct;68(10):2067-2074. doi: 10.4103/ijo.IJO_1191_19. Indian J Ophthalmol. 2020. PMID: 32971611 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources